US Family Health Plan
Prior Authorization Request Form for
telotristat (Xermelo)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be **faxed** to **855-273-5735**

OR

The patient may attach the completed form to the prescription and **mail** it to:
Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? **Call 1-877-880-7007**

Prior authorization expires after one year. For renewal of therapy an initial Tricare prior authorization approval is required. **usfamilyhealth.org/rx-pa**

Step 1 **Please complete patient and physician information** (please print):

Patient Name:		Physician Name:	
Address:		Address:	
Sponsor ID #		Phone #:	
Date of Birth:		Secure Fax #:	

Step 2 **Please complete the clinical assessment:**

1. Has the patient received this medication under the TRICARE benefit in the last 6 months? *Please choose "No" if the patient did not previously have a TRICARE approved PA for Xermelo*	☐ Yes (subject to verification) Proceed to question **3**	☐ No Proceed to question **2**
2. Does the patient have a diagnosis of carcinoid syndrome diarrhea?	☐ Yes **Sign and date below**	☐ No **STOP** **Coverage not approved**
3. Has the patient had a decrease from baseline in the amount of average daily bowel movements?	☐ Yes proceed to question **4**	☐ No **STOP** **Coverage not approved**
4. Does the prescriber agree to continue to assess the patient for severe constipation and abdominal pain and discontinue the medication if either develops?	☐ Yes proceed to question **5**	☐ No **STOP** **Coverage not approved**
5. While taking Xermelo (telotristat) has the patient had severe constipation or has abdominal pain developed?	☐ Yes **STOP** **Coverage not approved**	☐ No **Sign and date below**

Step 3 **I certify the above is true to the best of my knowledge.** Please sign and date:

_____ _____
Prescriber Signature Date

[4 December 2019]